Cellectar Biosciences secured an oversubscribed $140 million financing led by Nantahala Capital to support the confirmatory study and FDA accelerated approval filing for its cancer drug iopofosine I 131, targeting Waldenström macroglobulinemia. The funding also supports development of CLR 125 for triple-negative breast cancer. Nantahala’s Andrew Gu will join Cellectar’s board, highlighting investor confidence. This financing validates Cellectar’s strategy to bring new targeted oncology therapies to market and advance its proprietary drug delivery platform.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
Lido corrected a reporting error in its stETH staking yield caused by a missed 32 ETH validator deposit. This omission briefly lowered the reported annual percentage rate (APR) from about 2.15% to 2.04%, but was quickly fixed with a rebase that adjus...
AT&T's baby bonds currently offer a 6.7% yield and trade at a 20% discount to par value due to elevated interest rates. The company reported solid Q2 results with $31.6 billion in revenue and $5.04 billion in net profit, ensuring strong coverage for ...
Michael Saylor shared a bitcoin acquisition chart for Strategy Inc., which holds 843,775 BTC worth about $54.36 billion and maintains a $3.225 billion cash reserve. The company recently raised $263.5 million by selling stock but did not buy more bitc...
Arthur Hayes, co-founder of BitMEX, purchased 1,290 ETH worth about $2.5 million, adding to growing interest in Ethereum as it consolidates below the critical $1,900 resistance level. Analysts are watching closely to see if ETH can break above $1,900...
